Local News

• Adolor Provides Entereg(R) (Alvimopan) Hospital Registration Update  Adolor announced that over 500 hospitals have now enrolled in the Entereg Access Support & Education Program was launched by Adolor and GlaxoSmithKline in June 2008, following approval of Entereg(R) capsules by the U.S. FDA in May.
  Adolor Corporation July 24, 2008  
• Applied Biosystems reports fourth quarter financial results  Applied Biosystems reported net revenues of $609.0 million for the fourth quarter of fiscal 2008, an increase of 9% over the prior year quarter of $557.3 million. The net effect of foreign currency on net revenues was a favorable impact of approximately 5% compared to the prior year quarter.
  Applied Biosystems July 24, 2008  
• Aspect Medical Systems reports second quarter 2008 financial results  Aspect Medical Systems reported product revenue of $25.2 million for Q2 2008, a 9% increase from $23.1 million in Q2 2007, and that total revenue was $25.2 million for Q2 2008, a 5% decline from $26.6 million in Q2 2007.
  Aspect Medical Systems, Inc. July 24, 2008  
• Celgene reports second quarter financial results  Celgene reported non-GAAP net income of $172.7 million for the quarter ended June 30, 2008 and net income of $119.9 million. Non-GAAP total revenue was $566.6 million for the quarter ended June 30, 2008, an increase of 63 percent from 2007. GAAP total revenue was $571.5 million.
  Celgene Corporation July 24, 2008  
• Invitrogen announces second quarter 2008 financial results  Invitrogen announced results for its second quarter ended June 30, 2008. Revenues for the second quarter were $368 million, an increase of 14.3 percent over the $322 million reported for the second quarter of 2007.
  Invitrogen Corporation July 24, 2008  
• Multithreaded supercomputer seeks software for data-intensive computing  Pacific Northwest National Laboratory and Cray Inc. lead a team that received $4 million to develop software for the newest breed of supercomputers to better tackle large networks of seemingly random data, applicable in internet security, power grid stability and complex biological networks.
  Pacific Northwest National Laboratory July 24, 2008  
• Emergent BioSolutions awarded $4.5 million in NIAID Grants  Emergent BioSolutions announced that it has secured two grants totaling over $4.5 million from The National Institute of Allergy and Infectious Diseases to fund the continued development of the company's rBOT and NGAV vaccine candidates.
  Emergent BioSolutions Inc. July 24, 2008  
• NxStage appoints Jonathan Silverstein to board of directors  NxStage Medical announced the addition of Jonathan Silverstein, General Partner of OrbiMed Advisors, to its Board of Directors. Mr. Silverstein is General Partner at OrbiMed, an asset management firm solely focused in healthcare with several billion in assets under management.
  NxStage Medical, Inc. July 24, 2008  
• Osiris Therapeutics closes Osteocel transaction worth up to $137 million  Osiris Therapeutics announced that it has closed its definitive agreement with NuVasive for the purchase of the Osteocel business in a transaction worth up to $137 million. The completion of the transaction allows Osiris to focus on the launch of its next generation stem cell therapies.
  Osiris Therapeutics, Inc. July 24, 2008  
• Lilly reports second-quarter results  Eli Lilly reported net income and earnings per share grew to $958.8 million in the 2008 second-quarter compared with second-quarter 2007 net income of $663.6 million. Sales increased 11 percent, to $5.150 billion.
  Eli Lilly and Company July 24, 2008  

   (next 10 articles)